Clinical Trial

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-10-08; most recent amendment 2025-02-06.
Status change: Not Yet Recruiting → Recruiting 2020-10-27
Trial Details
NCT Number NCT04586478
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions Non-Hodgkin's Lymphoma
Enrollment 60 participants
Start Date 2020-10-26
Primary Completion 2024-03-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-07